Extranodal NK / T-cell lymphoma, nasal type: new staging system and treatment strategies (Q37598368)

21 August 2017

1 reference

title

Extranodal NK / T-cell lymphoma, nasal type: new staging system and treatment strategies (English)

1 reference

extranodal NK/T-cell lymphoma, nasal type

21 August 2017

main subject

0 references

author name string

Tae Min Kim

series ordinal

1

1 reference

21 August 2017

Dae Seog Heo

series ordinal

2

1 reference

21 August 2017

publication date

19 August 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

100

1 reference

21 August 2017

issue

12

1 reference

21 August 2017

page(s)

2242-2248

1 reference

Sinonasal NK/T-cell lymphomas in the United States

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-Ameri

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Natural killer-cell malignancies: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Treatment outcome and prognostic factors for primary nasal lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

NK-cell neoplasms in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Nasal-type NK/T cell lymphoma: clinical features and treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

NK and NK-like T-cell lymphoma in extranasal sites: a comparative clinicopathological study according to site and EBV status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Primary lymphomas of the nasal cavity and paranasal sinuses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Selective apoptosis of natural killer-cell tumours by l-asparaginase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

CD94 transcripts imply a better prognosis in nasal-type extranodal NK/T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01319.X

10.1111/J.1349-7006.2009.01319.X

21 January 2018

Identifiers

DOI

1 reference

release_6ob3c2pntbfd7fvkortekegvni

21 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6ob3c2pntbfd7fvkortekegvni

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference